Globe Life Inc.

ticker: GL step: 01 generated: 2026-05-13 source: quick-research

Globe Life Inc. (GL) — Business Overview

Business Description

Globe Life is a life and supplemental health insurance holding company serving middle-income and working-class Americans, operating through direct sales distribution divisions. Its largest subsidiary is American Income Life (AIL), which sells through labor unions and worksite marketing. Other divisions include Liberty National (direct sales to middle-income), Family Heritage (supplemental health), and a Direct-to-Consumer segment. FY2025 revenue was ~$5.99B (+3.7% YoY); net income was $1.16B; EPS $14.07 (+14.6%). Note: The company faced a major short-seller attack in April 2024 (stock dropped 53% in one day); the SEC closed its investigation with no enforcement action, but a DOJ probe into AIL sales tactics remains ongoing.

Revenue Model

Two main insurance segments: (1) Life Insurance premiums — recurring monthly/annual premiums on whole life and term life policies; 78% of insurance underwriting margin; highly predictable once in force. (2) Supplemental Health Insurance premiums — cancer, accident, accident-only, and Medicare Supplement policies; recurring premiums growing as health insurance gaps expand. (3) Investment income — fixed-income portfolio backing insurance reserves; interest rate sensitive. Policies are sold through captive/affiliated sales forces (AIL agents, Liberty National agents, Family Heritage agents) and directly via mail/digital (declining direct-to-consumer segment). Simple, easy underwriting (Yes/No applications) enables high-volume issuance to non-affluent policyholders.

Products & Services

• American Income Life (AIL) — whole life and supplemental health for union members, credit card customers; 22% increase in life net sales (2025); primary growth engine
• Liberty National — term and whole life + supplemental health for middle-income households; direct sales workforce
• Family Heritage — supplemental health (cancer, accident) sold worksite; health net sales +71%
• Direct-to-Consumer — mail, TV, digital direct response; declining (-8% projected)
• Globe Life (brand) — direct mail life insurance; simple acceptance products
• Annuities — smaller segment; mostly in runoff/maintenance mode

Customer Base & Go-to-Market

Working-class and lower-middle-income Americans — the same demographic that Primerica targets but served through captive/affiliated sales agents (not MLM). Union members are a key AIL client base — Globe Life agents have embedded relationships with unions for decades, providing automatic touchpoint with new members. Direct-to-consumer serves older adults through TV/mail marketing (simplified issue, no medical exam products).

Competitive Position

Globe Life competes with Primerica, Aflac (supplemental health), and direct-response insurers (AARP/New York Life licensed products) for the middle/working-class segment. Competitive advantages: 78-year brand recognition, embedded union distribution, simple product design, and captive sales forces that create switching costs. Direct-to-consumer is structurally declining as digital competitors emerge, but AIL's worksite/union channel is defensible. The 2024 fraud allegations and DOJ probe represent a reputational and legal risk that complicates the competitive picture.

Key Facts

• Founded: 1900 (predecessor companies); current holding company organized in 2001
• Headquarters: McKinney, Texas
• Employees: ~7,000 (plus captive field force)
• Exchange: NYSE
• Sector / Industry: Financials / Life Insurance
• Market Cap: ~$9–11B

ticker: GL step: 04 generated: 2026-05-13 source: quick-research

Globe Life Inc. (GL) — Financial Snapshot

Income Statement Summary

FY2025: Revenue ~$5.99B (+3.7%); net income $1.16B; EPS $14.07 (+14.6%); net operating EPS $14.52. Strong recovery driven by: (1) AIL life net sales +22%; (2) health net sales +71% in some quarters; (3) post-COVID mortality normalization improving life underwriting margins; (4) $685M in share buybacks reducing share count. Q2 2025: adj EPS $3.27 (+10% YoY). Life premiums accounted for 78% of insurance underwriting margin. April 2024 short-seller attack caused temporary ~53% stock decline; SEC closed investigation with no enforcement action; DOJ probe into AIL sales tactics remains ongoing.

Cash Flow & Balance Sheet

Globe Life's valuation is significantly discounted vs. peers due to the ongoing DOJ probe and 2024 fraud allegation overhang. A forward P/E of ~10.69x and PEG of 0.55 imply the market is pricing meaningful legal risk. If the DOJ probe resolves without major penalties (as the SEC probe did), the discount could narrow significantly toward the sector average of 13–15x P/E.

Key Ratios (approximate)

• P/E: ~10–11x (forward); PEG: 0.55
• Revenue Growth (FY2025): +3.7%; Net income growth: +8.3%
• EPS Growth (FY2025): +14.6% (helped by buybacks reducing share count)
• Net margin: ~19.4% (FY2025)

Growth Profile

Globe Life is a slow-and-steady insurer that grows via premium rate increases, new policy sales through captive agents, and EPS amplification through buybacks. Revenue grew from $5.23B (FY2022) to $5.99B (FY2025) — 1.15x in 3 years. EPS grew faster ($10.07 → $14.07) as buybacks reduced shares outstanding and mortality normalized post-COVID. AIL is the growth engine (+22% life net sales), while direct-to-consumer is a secular drag. Health insurance is a growth opportunity — health net sales +71% in high-activity quarters.

Forward Estimates

• FY2026: Net operating EPS ~$14.45 (CFRA estimate); consensus ~$14–15
• Analyst consensus PT: $163.85 (13 analysts; 11 of 13 = Buy)
• 19% implied upside from recent prices (~$138)
• CFRA upgraded to Buy post-SEC clearance, citing undervaluation + earnings momentum
• Key variable: DOJ probe resolution timeline and penalty risk